Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 19, Number 3—March 2013


Effects of Vaccine Program against Pandemic Influenza A(H1N1) Virus, United States, 2009–2010

Rebekah H. Borse1, Sundar S. Shrestha, Anthony E. Fiore, Charisma Y. Atkins, James A. Singleton, Carolyn Furlow, and Martin I. MeltzerComments to Author 
Author affiliations: Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Table 8

Results of sensitivity analyses to estimate number of cases, hospitalizations, and deaths prevented by vaccination against influenza A(H1N1)pdm09 virus obtained with various vaccine effectiveness scenarios*

Outcomes prevented Base estimate of vaccine effectiveness (range)† Lower vaccine effectiveness (range)‡ Higher vaccine effectiveness (range)§
Clinical cases 1,029,157 (712,908–1,458,930) 639,449 (442,971–907,688) 1,418,678 (983,671–2,004,053)
Hospitalizations 6,240 (3,923–10,393) 3,857 (3,923–6,418) 8,674 (3,923–14,461)
Deaths 315 (201–520) 193 (124–319) 438 (279–723)

*Data reflect calculations made for scenario 6, outcomes of assuming different vaccine effectiveness.
†Assumed 62% effectiveness for all groups except those >65 y, for whom 43% effectiveness was assumed.
‡Assumed 40% effectiveness for all groups except the elderly, for whom 20% effectiveness was assumed.
§Assumed 85% effectiveness for all groups except the elderly, for whom 55% effectiveness was assumed.

Main Article

1Current affiliation: Merck & Co., Inc., Lansdale, Pennsylvania, USA.